News
DVA
180.06
+0.50%
0.89
DaVita Inc. Balances Solid Q2 With Emerging Risks
TipRanks · 17h ago
Stronger Q2 Earnings and Transplant Focus Might Change The Case For Investing In DaVita (DVA)
Simply Wall St · 23h ago
Berkshire Hathaway exits Constellation Brands, boosts Delta in Q2
TipRanks · 1d ago
Tracking Berkshire Hathaway Portfolio - Q2 2026 Update
Seeking Alpha · 2d ago
Berkshire Hathaway Doubles Down on Homebuilders, Makes Alphabet Top 10 Holding
Benzinga · 2d ago
DaVita (DVA) Stock Looks Discounted On Earnings While Returns Look Strong
Simply Wall St · 3d ago
Truist Financial Remains a Hold on DaVita (DVA)
TipRanks · 4d ago
DaVita (DVA) Q2 2026 Earnings Call Transcript
The Motley Fool · 5d ago
Noteworthy Tuesday Option Activity: MSTR, GME, DVA
NASDAQ · 5d ago
Ten large-cap healthcare stocks with strong Quant scores amid sector-wide rally
Seeking Alpha · 6d ago
Are Wall Street Analysts Bullish on DaVita Stock?
Barchart · 6d ago
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS), Lifestance Health Group (LFST) and DaVita (DVA)
TipRanks · 6d ago
Weekly Report: what happened at DVA last week (0803-0807)?
Weekly Report · 08/10 10:21
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus
Seeking Alpha · 08/09 13:05
DaVita Price Target Cut to $220.00/Share From $201.00 by TD Cowen
Dow Jones · 08/07 20:45
DaVita Raised to Buy From Hold by TD Cowen
Dow Jones · 08/07 20:45
TD Cowen Upgrades DaVita to Buy, Lowers Price Target to $220
Benzinga · 08/07 20:34
The Economy Lost Jobs, Wall Street Threw a Party: What Moved Markets This Week
Benzinga · 08/07 19:40
DaVita price target lowered to $215 from $250 at Truist
TipRanks · 08/07 14:10
DaVita Is Maintained at Hold by Truist Securities
Dow Jones · 08/07 13:25
More
Webull provides a variety of real-time DVA stock news. You can receive the latest news about Davita Inc through multiple platforms. This information may help you make smarter investment decisions.
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company's robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company's international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company's U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.